Seven Grand Managers LLC Buys New Position in Maplight Therapeutics, Inc. $MPLT

Seven Grand Managers LLC bought a new stake in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the fourth quarter, Holdings Channel reports. The fund bought 100,000 shares of the company’s stock, valued at approximately $1,756,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC bought a new position in Maplight Therapeutics in the 4th quarter valued at about $6,835,000. Blue Owl Capital Holdings LP bought a new position in Maplight Therapeutics in the 4th quarter valued at about $5,745,000. Finally, Strs Ohio acquired a new stake in Maplight Therapeutics in the 4th quarter valued at about $53,000.

Maplight Therapeutics Trading Up 0.3%

Shares of NASDAQ MPLT opened at $29.55 on Thursday. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $33.28. The company has a market capitalization of $1.26 billion and a price-to-earnings ratio of -0.72. The firm has a 50-day moving average of $25.75 and a two-hundred day moving average of $20.29.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). As a group, research analysts predict that Maplight Therapeutics, Inc. will post -4.45 earnings per share for the current year.

Insider Activity

In other Maplight Therapeutics news, insider Erin Pennock Foff sold 4,438 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $28.54, for a total transaction of $126,660.52. Following the completion of the sale, the insider directly owned 346,059 shares of the company’s stock, valued at approximately $9,876,523.86. This represents a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 118,235 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the sale, the chief executive officer directly owned 1,394,094 shares of the company’s stock, valued at $37,905,415.86. This represents a 7.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 495,244 shares of company stock valued at $14,079,461 over the last ninety days. Corporate insiders own 3.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MPLT shares. Craig Hallum started coverage on shares of Maplight Therapeutics in a report on Thursday, May 21st. They issued a “buy” rating and a $43.00 price target for the company. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $45.00 price target for the company. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, TD Cowen started coverage on shares of Maplight Therapeutics in a report on Tuesday, April 7th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.89.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.